Fresh Tracks Therapeutics IncNASDAQ:FRTXNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.7880
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots0.7600/ 1
- Ask / Lots0.7880/ 34
- Open / Previous Close0.0000 / 0.7880
- Day Range---
- 52 Week Range
- Volume1
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | FRTX |
|---|---|---|
| 09:32 ET | 881 | 0.810101 |
| 09:34 ET | 165 | 0.81 |
| 09:36 ET | 1200 | 0.8101 |
| 09:41 ET | 633 | 0.8101 |
| 09:59 ET | 100 | 0.810101 |
| 10:01 ET | 500 | 0.8299 |
| 10:10 ET | 4000 | 0.829799 |
| 10:12 ET | 200 | 0.8113 |
| 10:17 ET | 100 | 0.8104 |
| 10:19 ET | 260 | 0.8101 |
| 10:21 ET | 371 | 0.81 |
| 10:24 ET | 500 | 0.8059 |
| 10:28 ET | 829 | 0.8052 |
| 10:35 ET | 100 | 0.8055 |
| 10:39 ET | 2101 | 0.8055 |
| 10:48 ET | 200 | 0.829799 |
| 11:09 ET | 100 | 0.8045 |
| 11:33 ET | 200 | 0.82 |
| 11:36 ET | 100 | 0.82 |
| 11:47 ET | 740 | 0.8204 |
| 11:49 ET | 572 | 0.82 |
| 11:51 ET | 100 | 0.8201 |
| 11:54 ET | 100 | 0.8201 |
| 11:56 ET | 1853 | 0.8102 |
| 12:12 ET | 1011 | 0.8045 |
| 12:30 ET | 100 | 0.8045 |
| 12:36 ET | 436 | 0.8005 |
| 12:43 ET | 640 | 0.8197 |
| 01:01 ET | 3004 | 0.81 |
| 01:08 ET | 36982 | 0.79 |
| 01:14 ET | 1600 | 0.7756 |
| 01:15 ET | 15652 | 0.7627 |
| 01:17 ET | 796 | 0.7647 |
| 01:19 ET | 2600 | 0.7655 |
| 01:21 ET | 2500 | 0.7675 |
| 01:24 ET | 200 | 0.795 |
| 01:28 ET | 260 | 0.7949 |
| 01:33 ET | 2290 | 0.76 |
| 01:55 ET | 822 | 0.767 |
| 02:02 ET | 250 | 0.7944 |
| 02:08 ET | 1600 | 0.78 |
| 02:09 ET | 100 | 0.778501 |
| 02:13 ET | 223 | 0.7789 |
| 02:38 ET | 980 | 0.7899 |
| 02:40 ET | 1000 | 0.7899 |
| 02:45 ET | 300 | 0.775 |
| 03:09 ET | 208 | 0.7812 |
| 03:21 ET | 900 | 0.795 |
| 03:41 ET | 2154 | 0.7701 |
| 03:43 ET | 300 | 0.7702 |
| 03:45 ET | 1600 | 0.7745 |
| 03:52 ET | 1000 | 0.7878 |
| 03:56 ET | 129 | 0.775 |
| 03:57 ET | 1946 | 0.7616 |
| 03:59 ET | 1157 | 0.788 |
Mar 13, 2023
BRIEF-Fresh Tracks Therapeutics Inc - Currently Maintains Up To $1.0 Million In Cash Deposits At Svb, from 5:35PM ET on Monday Mar 13, 2023 by Thomson Reuters
5:35PM ET on Monday Mar 13, 2023 by Thomson Reuters
Mar 8, 2023
BUZZ-U.S. STOCKS ON THE MOVE-Diversey, DocuSign, Stitch Fix, Campbell Soup , from 9:14AM ET on Wednesday Mar 08, 2023 by Thomson Reuters
9:14AM ET on Wednesday Mar 08, 2023 by Thomson ReutersInvestors Cautious Ahead of More Powell Testimony, Stifling US Equity Futures, from 8:54AM ET on Wednesday Mar 08, 2023 by MT Newswires
8:54AM ET on Wednesday Mar 08, 2023 by MT NewswiresThinking about buying stock in Rigel Pharmaceuticals, Maxeon Solar Technologies, Kimball International, Diversey Holdings, or Fresh Tracks Therapeutics?, from 8:30AM ET on Wednesday Mar 08, 2023 by PR Newswire
8:30AM ET on Wednesday Mar 08, 2023 by PR NewswireTop Premarket Gainers, from 7:45AM ET on Wednesday Mar 08, 2023 by MT Newswires
7:45AM ET on Wednesday Mar 08, 2023 by MT Newswires
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Fresh Tracks Therapeutics Inc | 2.4M | -0.1x | --- |
AnPac Bio-Medical Science Co Ltd | 12.7M | 0.0x | --- |
Senestech Inc | 2.8M | -0.1x | --- |
Pharmagreen Biotech Inc | 2.3M | -1.9x | --- |
Endonovo Therapeutics Inc | 2.8M | -0.7x | --- |
Allarity Therapeutics Inc | 2.5M | 0.0x | --- |
Company Information
Fresh Tracks Therapeutics, Inc., formerly Brickell Biotech, Inc., is a clinical-stage pharmaceutical company engaged in transforming patient lives through the development of differentiated prescription therapeutics. Its pipeline is focused on providing existing treatment paradigms and features several new molecular entities that inhibit novel targets with potential for autoimmune, inflammatory, and other debilitating diseases. The Company’s strategy is exploring therapies by identifying, pursuing, and developing therapeutics that can help people struggling with autoimmune, inflammatory and other debilitating diseases. Its pipeline includes FRTX-02, FRTX-10, Kinase Inhibitors and FRTX-03. Its lead program, FRTX-02, is a clinical-stage oral DYRK1A inhibitor for patients with autoimmune diseases to be administered in humans. Its FRTX-10 is a preclinical-stage stimulator of interferon genes (STING) inhibitor candidate. Its Kinase Inhibitors include compounds that inhibit prominent targets.
Contact Information
- Headquarters
- 5777 Central Ave Ste 102BOULDER, CO, United States 80301-2870
- Phone
- 720-505-4755
- Fax
- 302-655-5049
Executives
- Chairman of the Board, Co-Founder
- Reginald Hardy
- President, Chief Executive Officer
- Andrew Sklawer
- Chief Financial Officer, Chief Accounting Officer
- Albert Marchio
- Chief Operating Officer, Chief Research and Development Officer
- Deepak Chadha
- Chief Accounting Officer, Vice President - Finance
- Aaron Fox-Collis
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.4M |
|---|---|
Revenue (TTM) | $5.0M |
Shares Outstanding | 3.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.59 |
EPS | $-8.57 |
Book Value | $9.39 |
P/E Ratio | -0.1x |
Price/Sales (TTM) | 0.5 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -457.19% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
